Oral Presentation No. 64 Elevated soluble glycoprotein VI, a specific predictor of bleeding risk in patients with chronic coronary syndromes undergoing percutaneous coronary intervention

Abstract

Abstract Background Whether plasma levels of soluble glycoprotein VI (sGPVI) are able to predict ischemic or bleeding risk in patients with chronic coronary syndrome (CCS) undergoing percutaneous coronary intervention (PCI) is not known. The objective of this study was to answer this question. Material and methods The present study included 317 patients out of 334 patients of the ISAR-PLASTER trial (randomized trial of 2 doses of revacept vs. placebo), who underwent PCI for CCS and had baseline plasma sGPVI levels available. Patients were categorized into three groups according to tertiles of sGPVI: low (n = 106; sGPVI ≤ 9.5 ng/ml), intermediate (n = 106; sGPVI ≤ 16.2 ng/ml) and high tertile of sGPVI (n = 105; sGPVI ≥ 16.5 ng/ml). The composite of death and myocardial injury (MI) at 48 hours after randomization served as a measure of ischemic risk, and Bleeding Academic Research Consortium (BARC) type 1 to 5 bleeding at 30 days as a measure of bleeding risk. Results and conclusions Baseline plasma levels of sGPVI (before PCI and revacept administration) correlated with bleeding (bleeding incidence among low, intermediate and high sGPVI tertile: 11.8%, 13.6%, and 25.8%, respectively; P = 0.005), but not with ischemic events (incidence of death/MI among low, intermediate and high sGPVI tertile: 25.0%, 21.9%, and 26.9%, respectively; P = 0.70). Revacept did not interact with these associations. Elevated plasma sGPVI levels are associated with an increased risk of bleeding but not ischemic complications after PCI in patients with CCS. Funding German Center for Cardiovascular Research, Deutsches Herzzentrum München, Federal Ministry of Education and Research, and advanceCOR.